Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells-Reference-Cited by-同舟云学术

Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells

Published:2022-01-27 Issue:4 Volume:47 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Murase Yusuke¹,Hosoya Kenji¹,Sato Takachika¹,Kim Sangho¹,Okumura Masahiro¹

Affiliation:

1. Laboratory of Veterinary Surgery, Department of Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido 060‑0818, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Reference52 articles.

1. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting;Thorpe;Nat Rev Cancer,2015

2. PI3K and cancer: Lessons, challenges and opportunities;Fruman;Nat Rev Drug Discov,2014

3. Targeting the PI3K pathway in cancer: Are we making headway?;Janku;Nat Rev Clin Oncol,2018

4. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy;Wander;J Clin Invest,2011

5. The PI3K pathway as drug target in human cancer;Courtney;J Clin Oncol,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future;Veterinary Sciences;2024-05-02

2. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK);Journal of Enzyme Inhibition and Medicinal Chemistry;2023-07-24

3. Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets;Veterinary Sciences;2023-06-05